Ifm_05-may 2022 [FREE]

Lenalidomide was the primary drug used for maintenance in this study. Key Findings:

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. IFM_05-May 2022

If you are looking for guidance based on this study's results: Lenalidomide was the primary drug used for maintenance

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. Early versus Late Discontinuation of Maintenance Therapy in

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice.